President Donald Trump’s drug pricing-push is about to run into what might be its most potent opponent yet: America’s senior citizens.
On Monday afternoon, the Trump administration released a proposal for rules that would make it easier for Medicare Part D prescription-drug plans to negotiate prices for a broader array of medicines than they do currently. That’s arguably a good thing. But in order for this effort to have a real impact, plans will likely have to be able to restrict the access that senior citizens have had for more than a decade to certain classes of drugs.
